Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09 janv. 2025 16h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces First AML Patients Dosed with
Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces Positive Decision by Nasdaq Hearings Panel
19 déc. 2024 16h05 HE
|
Aptose Biosciences, Inc.
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12 déc. 2024 10h15 HE
|
Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03 déc. 2024 07h30 HE
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
25 nov. 2024 16h15 HE
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30 août 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
15 août 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19 juil. 2024 17h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Annual and Special Meeting of Shareholders
18 juin 2024 17h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03 juin 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market
Under Nasdaq Rules